Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052130 | 1.00 | GLA (0.39) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL4060088 | 0.88 | GLA (0.39) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL4060091 | 0.88 | GLA (0.39) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL7252158 | 0.88 | GLA (0.44) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL7252154 | 0.88 | GLA (0.44) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL7248729 | 0.83 | GLA (0.41) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL7248727 | 0.83 | GLA (0.41) | GLAPAX8KDM4ENPC1ALDH1A1 | |
| SCHEMBL4231281 | 0.82 | CYSLTR1 (0.36) | GLACYSLTR2CYSLTR1 | |
| SCHEMBL4231288 | 0.82 | CYSLTR1 (0.36) | GLACYSLTR2CYSLTR1 | |
| SCHEMBL7243489 | 0.82 | GLA (0.40) | GLAPAX8KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | GLA 1226/4885PAX8 4842/4885KDM4E 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.